Printer Friendly

University of British Columbia obtains United States patent.

University of British Columbia (Vancouver, Canada) has patented a polypeptide, called Tir (for translocated intimin receptor, which is secreted by attaching and effacing pathogens, such as the enteropathogenic and enterohemorrhagic E. coli. These bacterial pathogens inserts their own receptors into mammalian cell surfaces, to which the bacterial pathogen then adheres to trigger additional host signaling events and actin nucleation. Diagnosis of disease caused by pathogenic E. coli can be performed by the use of antibodies which bind to Tir to detect the protein or the use of nucleic acid probes for detection of nucleic acids encoding Tir polypeptide. Isolated nucleic acid sequences encoding Tir polypeptide, Tir peptides, a recombinant method for producing recombinant Tir, antibodies which bind to Tir, and a kit for the detection of Tir-producing E. coli are provided. A method of immunizing a host with Tir to induce a protective immune response to Tir or a second polypeptide of interest is also provided. A method for screening for compounds which interfere with the binding of bacterial pathogens to their receptors is further provided. (US 7,208,574)
COPYRIGHT 2007 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:for translocated intimin receptor
Publication:BIOTECH Patent News
Article Type:Brief article
Geographic Code:1USA
Date:Apr 1, 2007
Previous Article:Quigley Granted Patent For Prophylactic and Anti-Transmissivity Uses of an Anti-Microbial Composition.
Next Article:Maniv Energy obtains United States patent.

Related Articles
Enteropathogenic E. coli, Salmonella, and Shigella: Masters of Host Cell Cytoskeletal Exploitation.
Typical and atypical Enteropathogenic Escherichia coli. (Synopsis).
Human milk secretory antibodies against attaching and effacing Escherichia coli antigens. (Research).
Emerging enteropathogenic Escherichia coli strains?
University of Michigan obtains United States patent.
Sirna Therapeutics obtains patents covering siRNAs targeting VEGF and HCV.
Advanced Research and Technology obtains United States patent.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters